This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luo, S. Articles by Labrie, F. Search for Related Content PubMed PubMed Citation Articles by Luo, S. Articles by Labrie, F.

Effect of Dehydroepiandrosterone on Bone Mass, Serum Lipids, and Dimethylbenz(a)anthracene-Induced Mammary Carcinoma in the Rat¹

MRC Group in Molecular Endocrinology, CHUL Research Center and Laval University, Quebec,G1V 4G2, Canada

Address all correspondence and requests for reprints to: Fernand Labrie, Medical Research Council of Canada Group in Molecular Endocrinology, le Centre Hospitalier de l’Université Laval Research Center, 2705 Laurier Boulevard, Québec (Québec), G1V 4G2, Canada.

The present study investigated the effect of dehydroepiandrosterone (DHEA) on bone mass and serum lipids in the rat with dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma. The animals received DHEA once daily, percutaneously, at the dose of 5, 10, or 20 mg for 9 months following a single dose of 20 mg DMBA at 50–52 days of age. Bone mineral content (BMC) and bone mineral density (BMD) of total skeleton, lumbar spine, and femur were measured by dual energy x-ray absorptiometry. A 9-month treatment with DHEA increased BMC and BMD of total skeleton by 14.2% to 14.5% (all P < 0.01) and 6.7% to 8.3% (all P < 0.01), respectively. Similarly, femoral BMC and BMD were stimulated by 13.6% to 14.7% (all P < 0.05) and by 8.1% to 9.5% (all P < 0.01), respectively. In addition, BMD of lumbar spine was increased by 10.4% to 10.8% (all P < 0.05), whereas the 9.4% to 11.1% increment in BMC of lumbar spine was not statistically significant. Treatment with DHEA led to 26% (NS), 60% (P < 0.01), and 62% (P < 0.01) decreases in serum triglyceride levels at the same doses. On the other hand, no significant change in serum cholesterol concentrations was observed. Two hundred and seventy-nine days after DMBA administration, the incidence of mammary carcinoma had decreased from 95% in control animals to 73% (P < 0.05), 57% (P < 0.01), and 38% (P < 0.01) at the daily percutaneous doses of 5, 10, and 20 mg of DHEA, respectively. Moreover, the mean tumor number per tumor-bearing animal and the mean tumor area per tumor-bearing animal were also reduced by the same treatments. DHEA increased serum total alkaline phosphatase activity and decreased urinary calcium excretion, but had no effect on the urinary ratio of hydroxyproline to creatinine and urinary phosphorus excretion.

These data show that DHEA exerts a stimulatory effect on bone mass and an inhibitory effect on serum triglycerides, as well as a preventive effect on the development of mammary carcinoma induced by DMBA in the rat. Such data suggest that while decreasing the risk of breast cancer, DHEA replacement therapy could also exert beneficial effects on the bone and lipid metabolism in women receiving DHEA replacement therapy.

This article has been cited by other articles:

				F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]

				S. Dharia, A. Slane, M. Jian, M. Conner, A. J. Conley, R. M. Brissie, and C. R. Parker Jr. Effects of Aging on Cytochrome B5 Expression in the Human Adrenal Gland J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4357 - 4361. [Abstract] [Full Text] [PDF]

				J. Simard, M.-L. Ricketts, S. Gingras, P. Soucy, F. A. Feltus, and M. H. Melner Molecular Biology of the 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Gene Family Endocr. Rev., June 1, 2005; 26(4): 525 - 582. [Abstract] [Full Text] [PDF]

				W. Somboonporn and S. R. Davis Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women Endocr. Rev., June 1, 2004; 25(3): 374 - 388. [Abstract] [Full Text] [PDF]

				F. A. Abu-Bedair, B. A. El-Gamal, N. A. Ibrahim, and A. A. El-Aaser Serum Lipids and Tissue DNA Content in Egyptian Female Breast Cancer Patients Jpn. J. Clin. Oncol., June 1, 2003; 33(6): 278 - 282. [Abstract] [Full Text] [PDF]

				F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone Endocr. Rev., April 1, 2003; 24(2): 152 - 182. [Abstract] [Full Text] [PDF]

				H. P. Ciolino, C. J. MacDonald, and G. C. Yeh Inhibition of Carcinogen-activating Enzymes by 16{alpha}-Fluoro-5-androsten-17-one Cancer Res., July 1, 2002; 62(13): 3685 - 3690. [Abstract] [Full Text] [PDF]

				A. J. Kahn and B. Halloran Dehydroepiandrosterone Supplementation and Bone Turnover in Middle-Aged to Elderly Men J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1544 - 1549. [Abstract] [Full Text] [PDF]

				H. P. Ciolino and G. C. Yeh The Steroid Hormone Dehydroepiandrosterone Inhibits CYP1A1 Expression in Vitro By a Post-transcriptional Mechanism J. Biol. Chem., December 3, 1999; 274(49): 35186 - 35190. [Abstract] [Full Text] [PDF]